Marinomed Biotech’s €5.4 Million Investment Agreement With Nice&Green

Herbst Kinsky advised Marinomed Biotech.

Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, has secured EUR5.4 million in financing via a flexible Convertible Notes Funding Programme (CNFP) from the Swiss investment firm Nice & Green.

Under this convertible bond program, Marinomed Biotech AG is entitled to issue up to 18 tranches of zero coupon bonds in the amount of up to EUR 300,000 per tranche during the contractual term of approximately 23 months.

This flexible financial instrument will enable Marinomed to advance its scientific and clinical programs for both its virus-blocking Carragelose technology and its equally proprietary Marinosolv platform for the solubilisation of active pharmaceutical ingredients.

The Herbst Kinsky team was led by Philipp Kinsky (Picture) with support from Georg Durstberger.

Involved fees earner: Georg Durstberger – Herbst Kinsky; Philipp Kinsky – Herbst Kinsky;

Law Firms: Herbst Kinsky;

Clients: Marinomed Biotech AG ;

Author: Federica Tiefenthaler